Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
Fortunato MorabitoGiovanni TripepiGiovanni Del PoetaFrancesca Romana MauroGianluigi RedaPaolo SportolettiLuca LaurentiMarta CosciaYair HerishanuSabrina BossioMarzia VarettoniRoberta MurruAnnalisa ChiarenzaAndrea VisentinAdalgisa CondoluciRiccardo MoiaDaniela PietrasantaGiacomo LosetoUgo ConsoliIlaria ScortechiniFrancesca Maria RossiAntonella ZucchettoHamdi Al-JanazrehErnesto VignaEnrica Antonia MartinoFrancesco MendicinoRamona CassinGraziella D'ArrigoSara GalimbertiAngela RagoIlaria AngelettiAnnalisa BiagiIlaria Del GiudiceRiccardo BombenAntonino NeriGilberto FronzaPaola MenichiniPaola MenichiniGiovanna CutronaOzren JaksicDavide RossiFrancesco Di RaimondoAntonio CuneoGianluca GaidanoAaron PolliackLivio TrentinRobin FoàManlio FerrariniValter GatteiMassimo GentilePublished in: European journal of haematology (2021)
Although our analysis presents some constraints, that is, the unavailability of additional potential confounders, and the retrospective nature of the study, this observation may be of help for the daily clinical practice, particularly in the absence of randomized trials comparing the two schedules.